Tendência da mortalidade por Paracoccidioidomicose no Brasil ­ 1996 a 2020 / Mortality trends due to Paracoccidioidomycosis in Brazil ­ 1996 to 2020

Objetivo: Analisar a tendência da mortalidade por paracoccidioidomicose (PCM) e caracterizar o perfil sociodemográfico no Brasil e suas regiões geográficas numa série temporal de 25 anos. Métodos: Trata-se de estudo ecológico de séries temporais. Considerou-se como participantes do estudo a população brasileira dividida em faixas etárias, que tiveram como causa básica do óbito a PCM. Para calcular a variação percentual anual (VPA) dos coeficientes, na análise de tendência, foi utilizada a regressão de Prais-Winsten. Os coeficientes de mortalidade foram calculados a nível nacional, segundo as regiões geográficas, sexo e faixa etária e proporcional para as demais variáveis. Resultados: De acordo com os resultados deste estudo, ocorreram 2.101 óbitos por PCM no Brasil. A tendência ao longo dos 25 anos evidenciou um comportamento estável nas regiões Norte e Nordeste. Já no Sul, Sudeste e Centro-Oeste houve uma tendêndia de queda. A mortalidade média no Brasil foi de 84,04/100 mil hab., VPA -3,29 (IC 95% -2,43; -4,14). Levando em consideração a análise dos aspectos sociodemográficos, houve um predomínio de escolaridade ignorada (764; 36%), raça/ cor da pele branca (1.109; 53%), estado civil misto: casado (942; 45%) e solteiro (640; 30%), local de ocorrência do óbito predominantemente no âmbito hospitalar (1.852; 88%). Conclusão: Tanto no Brasil como nas regiões geográficas Sudeste, Sul e Centro-Oeste a mortalidade por PCM apresentou-se com tendência temporal decrescente. Já nas regiões Nordeste e Norte a tendência foi estacionária. O perfil sociodemográfico dos pacientes que foram a óbito apontou para sexo masculino, adultos, de baixa escolaridade, brancos e casados.

Objective: To analyze the trend in mortality from paracoccidioidomycosis (PCM) and characterize the sociodemographic profile in Brazil and its geographic regions in a 25-year time series. Methods: This is an ecological time series study. The study participants were the Brazilian population divided into age groups whose underlying cause of death was PCM. To calculate the annual percentage change (VPA) of the coefficients in the trend analysis, the Prais-Winsten regression was used. National mortality coefficients were calculated according to geographic regions, sex and age group and proportional to the other variables. Results: According to this study, there were 2,101 deaths from PCM in Brazil. The trend over the 25 years showed stable behavior in the North and Northeast regions. In the South, Southeast, and Midwest, there was a downward trend. The average mortality in Brazil was 84.04/100,000 inhab., VPA -3.29 (95% CI -2.43; -4.14). According to the analysis of sociodemographic aspects, there was a predominance of ignored schooling (764 deaths; 36%), white race/skin color (1,109; 53%), mixed marital status: married (942; 45%) and single (640; 30%), and place of death predominantly in the hospital environment (1,852; 88%). Conclusion: In Brazil and in the Southeast, South, andMidwest geographic regions, mortality from PCM showed a decreasing temporal trend. In the Northeast and North regions, the trend was stationary. The sociodemographic profile of the dying patients indicated males, adults, with low education, white, and married.

Morbi-mortalidade e gastos hospitalares com idosos de Minas Gerais, Brasil / Morbis-mortality and hospital costs with elderly people from Minas Gerais, Brazil / Morbi-mortalidad y gasto hospitalario en ancianos de Minas Gerais, Brasil

Introdução: O envelhecimento populacional é uma realidade em todo o mundo, representando um desafio significativo para os sistemas de saúde. Objetivo: Descrever o perfil de morbidades e os gastos relacionados a internações de idosos em comparação aos adultos registradas no estado de Minas Gerais, Brasil, entre 2008 e 2017. Métodos: Estudo descritivo, de corte transversal, com dados do DATASUS e com base na CID-10. Resultados: Embora o maior número de internações esteja na faixa etária adulta, a proporção de gastos é maior com os idosos, com maior prevalência entre doenças mentais e comportamentais, osteomusculares e do tecido conjuntivo, seguidos das doenças de causas externas e do aparelho circulatório. Conclusão: Sugere-se a adoção de políticas mais abrangentes e maior investimento em ações de promoção da saúde, prevenção de agravos e tratamento oportuno e adequado para as doenças mais prevalentes nos idosos, em especial na atenção primária à saúde.

Introduction: Population aging is a reality around the world, representing a significant challenge for health systems. Objective: To describe the profile of morbidities and spending related to hospitalizations of elderly in comparison to adults registered in the state of Minas Gerais, Brazil, between 2008 and 2017. Methods: Descriptive, cross-sectional study with data from DATASUS and based on ICD-10. Results: Although the highest number of hospitalizations is in the adult age group, the proportion of expenditures is higher with the elderly, with a higher prevalence among mental and behavioral diseases, osteomuscular diseases and connective tissue, followed by diseases of external causes and the circulatory system. Conclusion: It is suggested to adopt more comprehensive policies and to invest more in actions to promote health, prevention of diseases and timely and adequate treatment for the most prevalent diseases in the elderly, especially in primary health care.

Introducción: El envejecimiento de la población es una realidad mundial, que representa un importante desafío para los sistemas de salud. Objetivo: Describir el perfil de morbilidad y los gastos relacionados con las internaciones de los ancianos en comparación con los adultos registrados en el estado de Minas Gerais (Brasil) entre 2008 y 2017. Métodos: estudio descriptivo, transversal con datos DATASUS y basado en CID-10. Resultados: Aunque el mayor número de internaciones se encuentra en el grupo de edad adulta, la proporción de gastos es mayor con los ancianos, con una mayor prevalencia entre las enfermedades mentales y conductuales, las enfermedades osteomusculares y el tejido conjuntivo, seguidas de enfermedades de causas externas y el aparato circulatorio. Conclusión: Se sugiere adoptar políticas más amplias e invertir más en acciones para promover la salud, prevenir las agravaciones y el tratamiento oportuno y adecuado de las enfermedades más prevalentes en las personas de edad, especialmente en la atención primaria de la salud.

Potencial terapêutico dos canabinoides na ansiedade e depressão: uma revisão integrativa da literatura / Therapeutic potential of cannabinoids in anxiety and depression: an integrative review of the literature / Potencial terapéutico de canabinoides en ansiedad y depresión: una revisión integrativa de la literatura

Introdução: Os transtornos psiquiátricos, principalmente ansiedade e depressão, são queixas muito prevalentes na população mundial. Atualmente, esse fato move a comunidade científica a realizar estudos para avaliar alternativas que possam contribuir no tratamento dessas doenças. Por isso, a Cannabis Medicinal (CM) vem ganhando espaço na sociedade e parece ser uma opção terapêutica viável e vantajosa. Objetivo: Evidenciar os possíveis usos terapêuticos dos componentes presentes na planta Cannabis no manejo da ansiedade e depressão. Métodos: Trata-se de uma revisão bibliográfica integrativa, elaborada a partir de trabalhos científicos acerca da ação da Cannabis Medicinal como uma alternativa para o tratamento da ansiedade e depressão. Foram considerados artigos originais e completos publicados em português, espanhol e inglês nos últimos dez anos, de 2013 até 2023, obtidos nas plataformas SCIELO, PUBMED e LILACS. Resultados: As substâncias presentes na planta Cannabis, principalmente o Canabidiol (CBD), parecem ser uma opção promissora e potencialmente benéfica, especialmente para os casos que não respondem aos tratamentos convencionais. Conclusão: A partir dos estudos analisados, evidencia-se que os estudos atuais disponíveis sobre a eficácia dos canabinoides no tratamento dos transtornos mentais são de qualidade variável. Sendo assim, apesar da CM ser uma possível opção para o tratamento de transtornos mentais, ainda se faz necessária a realização de mais pesquisas para elucidar plenamente como funcionaria sua utilização na prática clínica. PALAVRAS-CHAVE: Uso Terapêutico da Cannabis; Depressão; Ansiedade; Revisão Integrativa.

Introduction: Psychiatric disorders, mainly anxiety and depression, are very prevalent complaints in the world population. At the moment, this fact is driving the scientific community to carry out studies to evaluate alternatives that may contribute towards the treatment of these diseases. For this reason, Medicinal Cannabis (CM) has been gaining space in society and seems to be a viable and advantageous therapeutic option. Objective: To show the possible therapeutic uses of the components present in the Cannabis plant in the management of anxiety and depression. Methods: It is an integrative bibliographic review, elaborated from scientific papers about the action of Medicinal Cannabis as an alternative for the treatment of anxiety and depression. They were considered original and complete articles published in Portuguese, Spanish and English in the last ten years, from 2013 until 2023, obtained on the platforms SCIELO, PUBMED and LILACS. Results: The substances present in the Cannabis plant, mainly Cannabidiol (CBD), seem to be a promising and potentially beneficial option, especially for cases that do not respond to conventional treatments. Conclusion: From the studies analyzed, it is evident that the current available studies on the efficacy of cannabinoids in the treatment of mental disorders are of variable quality. Therefore, although CM is a possible option for the treatment of mental disorders, it is still necessary to carry out more research to fully elucidate how its use would work in clinical practice.

Introducción: los trastornos psiquiátricos, principalmente la ansiedad y la depresión, son quejas muy frecuentes en la población mundial. Por el momento, este hecho está llevando a la comunidad científica a realizar estudios para evaluar alternativas que puedan contribuir al tratamiento de estas enfermedades. Por esta razón, el Medicamento de Cannabis (CM) ha venido ganando espacio en la sociedad y parece ser una opción terapéutica viable y ventajosa. Objetivo: destacar los posibles usos terapéuticos de los componentes presentes en la planta de Cannabis en el manejo de la ansiedad y la depresión. Métodos: Se trata de una revisión bibliográfica integradora, elaborada sobre la base de un trabajo científico sobre la acción del Medicinal Cannabis como alternativa para el tratamiento de la ansiedad y la depresión. Se consideraron artículos originales y completos publicados en portugués, español e inglés en los últimos 10 años de 2013 a 2023, obtenidos en las plataformas SCIELO, PUBMED y LILACS. Resultados: Las sustancias presentes en la planta Cannabis, principalmente Canabidiol (CBD), parecen ser una opción prometedora y potencialmente beneficiosa, especialmente en los casos que no responden a tratamientos convencionales. Conclusión: De los estudios analizados se desprende que los estudios actuales disponibles sobre la eficacia de los cannabinoides en el tratamiento de los trastornos mentales son de calidad variable. Por lo tanto, aunque la MPC es una posible opción para el tratamiento de los trastornos mentales, todavía se necesita una investigación más profunda para explicar plenamente cómo funcionaría su uso en la práctica clínica.

LipoCardium: endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesions.

Atherosclerosis is a multifactorial inflammatory disease of blood vessels which decimates one in every three people in industrialized world. Despite the important newest clinical approaches, currently available strategies (e.g. nutritional, pharmacological and surgical) may only restrain the worsening of vascular disease. Since antiproliferative cyclopentenone prostaglandins (CP-PGs) are powerful anti-inflammatory agents, we developed a negatively charged liposome-based pharmaceutical formulation (LipoCardium) that specifically direct CP-PGs towards the injured arterial wall cells of atherosclerotic mice. In the blood stream, LipoCardium delivers its CP-PG contents only into activated arterial wall lining cells due to the presence of antibodies raised against vascular cell adhesion molecule-1 (VCAM-1), which is strongly expressed upon inflammation by endothelial cells and macrophage-foam cells as well. After 4 months in a high-lipid diet, all low-density lipoprotein receptor-deficient adult control mice died from myocardium infarction or stroke in less than 2 weeks, whereas LipoCardium-treated (2 weeks) animals (still under high-lipid diet) completely recovered from vascular injuries. In vitro studies using macrophage-foam cells suggested a tetravalent pattern for LipoCardium action: anti-inflammatory, antiproliferative (and pro-apoptotic only to foam cells), antilipogenic and cytoprotector (via heat-shock protein induction). These astonishing cellular effects were accompanied by a marked reduction in arterial wall thickness, neointimal hyperplasia and lipid accumulation, while guaranteed lifespan to be extended to the elderly age. Our findings suggest that LipoCardium may be safely tested in humans in a near future and may have conceptual implications in atherosclerosis therapy.

Atherosclerosis: a redox-sensitive lipid imbalance suppressible by cyclopentenone prostaglandins.

Disorders concerning the metabolism of plasma and intracellular lipids are hallmarks of atherosclerosis. However, failures in proper control of intracellular cholesterol balance, rather than simple cholesterol overloading due to augmented uptake, could fuel atherogenesis. Therefore, the understanding of atherosclerosis-associated lipid alterations, which feed an inflammatory microenvironment in the arterial wall, requires the meticulous investigation of several aspects of lipid synthesis, uptake and export from cells. In this regard, the presence of reactive cysteines in transcription factors and key enzymes of lipid metabolism may dictate cholesterol accumulation, and therefore the progression of vascular disease. The strong inhibitory effect of cysteine-reactant anti-inflammatory cyclopentenone prostaglandins (CP-PGs) over atherosclerosis progression in vivo (LipoCardium technology) symbolizes a new concept of atherosclerosis and its treatment. Results from this laboratory and those from other research groups have unraveled a novel facet in prostaglandin research in that CP-PGs may act as redox signals that guide lipid metabolism in atherosclerosis. By modifying enzymes (e.g., HMG-CoA reductase, ACAT and cholesteryl ester hydrolases) and transcription factors (e.g., NF-kappaB and Keap1) involved in inflammation and lipid metabolism, CP-PGs (especially those of A-series) induce pivotal changes in glutathione and lipid metabolism that completely arrest atherosclerosis progression. Hence, pharmacological manipulation of lipid metabolism by CP-PGs may be a novel and invaluable strategy for treating atherosclerosis. Also, a better understanding of why CP-PGs do not resolve inflammation physiologically may explain many unsolved questions and yield insights into atherogenesis and its termination.

Low expression of MRP1/GS-X pump ATPase in lymphocytes of Walker 256 tumour-bearing rats is associated with cyclopentenone prostaglandin accumulation and cancer immunodeficiency.

Immunosuppression is a life-threatening complication of late cancer stages. In this regard, overproduction in the host plasma of the anti-inflammatory cyclopentenone prostaglandins (CP-PGs), which are strongly antiproliferative at high concentrations, may impair immune function. In fact, lymphoid tissues of tumour-bearing rats accumulated large amounts of CP-PGs while the tumour tissue itself did not. Expression of the CP-PG-induced 72-kDa heat shock protein (hsp70) was elevated in lymphocytes from tumour-bearing animals related to controls. As the capacity for CP-PG uptake by lymphocytes is the same as tumour cells, we investigated whether the latter could overexpress the multidrug resistance-associated protein (MRP1/GS-X pump) which extrudes CP-PGs towards the extracellular space as glutathione S-conjugates. Walker 256 tumour cells extruded 15-fold more S-conjugates than lymphocytes from the same rats (p < 0.001). This did not appear to be related to deficiency in lymphocyte glutathione (GSH) metabolism, since the major GSH metabolic routes are consistent with CP-PG conjugation in lymphocytes. This was not the case, however, for the MRP1/GS-X pump activity in lymphocyte membranes (in pmol/min/mg protein: 3.1 +/- 1.7 from normal rats, 0.2 +/- 0.2 from tumour-bearing animals vs 64.3 +/- 7.0 in tumour cells) which was confirmed by Western blot analysis for MRP1 protein. Transfection of lymphocytes with MRP1 gene completely abolished CP-PG (0-40 microM) toxicity. Taken together, these findings suggest that CP-PG accumulation in lymphocytes may be, at least partially, responsible for cancer immunodeficiency. Clinical approaches for overexpressing MRP1/GS-X pump in lymphocytes could then play a role as a tool for the management of cancer therapeutics.